MEDIXALL GROUP INC (MDXL) Financials
Newest figures come from the 10-Q for Q3 FY2024, filed Sep 8, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDXL SEC filings page.
MEDIXALL GROUP INC (MDXL) reported $304K in revenue over the twelve months to Sep 30, 2024, up 29.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing dependence remains dominant: modest revenue recovery sits beside a severely strained balance sheet and persistent operating cash outflows.
Across the last two reported years, revenue recovered while gross margin fell from100.0% to23.6% , indicating newer sales carry direct costs rather than simply scaling the prior model. Operating cash flow also became less negative as SG&A was reduced, showing that cash pressure eased through cost reduction rather than demonstrated profitability.
At FY2023 year-end, liabilities were roughly 33.4x assets while the current ratio was only 0.0x, leaving the financing structure dominated by obligations rather than operating resources. Negative equity of
The company burned
Financial Health Signals
MEDIXALL GROUP INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MEDIXALL GROUP INC passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
MEDIXALL GROUP INC generated $39K in revenue in Q3 2024. This represents a decrease of 40.7% from the same quarter a year earlier. Against the prior quarter it is down 26.5%.
MEDIXALL GROUP INC reported $264K in net income in Q3 2024. This represents an increase of 129.1% from the same quarter a year earlier. Against the prior quarter it is up 154.3%.
MEDIXALL GROUP INC earned $0.00 per diluted share (EPS) in Q3 2024. This represents an increase of 100.0% from the same quarter a year earlier.
Not reported for Q3 2024.
Cash & Balance Sheet
MEDIXALL GROUP INC held $32K in cash as of Q3 2024; long-term debt is not reported for that period.
Not reported for Q3 2024.
Not reported for Q3 2024.
Margins & Returns
MEDIXALL GROUP INC's gross margin was 57.4% in Q3 2024, indicating the percentage of revenue retained after direct costs. This is up 53.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 15.0 percentage points.
Not reported for Q3 2024.
Not shown for Q3 2024: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2024.
Capital Allocation
None of these metrics is reported for Q3 2024.
MDXL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39K-40.7% | $53K-26.1% | $118K+51.7% | $94K+366.8% | $66K+215.6% | $72K+590.9% | $78K+884.8% | $20K+188.0% |
| Cost of Revenue | $17K-73.8% | $15K-59.0% | $50K-43.6% | $48K | $63K | $36K | $89K | $0 |
| Gross Profit | $22K+819.6% | $38K+6.4% | $68K+687.2% | $46K+127.7% | $2K-88.3% | $36K+247.2% | -$12K-245.9% | $20K |
| SG&A Expenses | $148K-8.6% | $166K-21.8% | $170K-38.4% | $356K-41.8% | $162K-40.6% | $212K-73.0% | $275K-82.0% | $611K-51.1% |
| Interest Expense | $46K+24.2% | $106K+221.3% | $180K+77.1% | $475K+75.4% | $37K | $33K | $102K | $271K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $264K+129.1% | -$486K+50.4% | -$487K+60.2% | N/A | -$908K+16.2% | -$979K+37.0% | -$1.2M+49.3% | N/A |
| EPS (Basic) | $0.00+100.0% | $0.00+100.0% | $0.00+100.0% | -$0.010.0% | -$0.010.0% | -$0.010.0% | -$0.01+50.0% | -$0.01+50.0% |
| EPS (Diluted) | $0.00+100.0% | $0.00+100.0% | $0.00+100.0% | -$0.010.0% | -$0.010.0% | -$0.01 | -$0.01+50.0% | -$0.01+50.0% |
| Diluted Shares (Avg) | 162M+24.4% | 139M+8.9% | 134M+9.7% | N/A | 130M+11.6% | 127M | 122M+6.6% | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Operating Income, EBITDA.
MDXL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $220K-51.7% | $229K-53.4% | $272K-56.0% | $201K-76.7% | $456K-55.4% | $492K-57.7% | $618K-49.5% | $862K-23.8% |
| Current Assets | $47K+256.9% | $43K+95.1% | $72K+1148.8% | $14K+23.5% | $13K-86.3% | $22K-88.4% | $6K-97.5% | $11K-96.6% |
| Cash & Equivalents | $32K+230.2% | $33K+75.6% | $54K+2250.9% | $11K+213.8% | $10K-87.2% | $19K-89.3% | $2K-97.8% | $3K-94.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $12K | $7K | $15K | $0 | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.8M-32.7% | $7.7M+44.9% | $7.3M+45.9% | $6.7M+48.4% | $5.7M+44.9% | $5.3M+82.2% | $5.0M+162.6% | $4.5M+207.9% |
| Current Liabilities | $3.8M-33.5% | $7.7M+44.1% | $7.2M+44.7% | $6.7M+54.3% | $5.7M+54.5% | $5.3M+296.4% | $5.0M+304.1% | $4.3M+254.3% |
| Non-Current Liabilities | $46K | $46K | $62K | $26K-86.0% | $0-100.0% | $0-100.0% | $0-100.0% | $189K-23.1% |
| Total Equity | -$3.6M+31.1% | -$7.5M-54.9% | -$7.0M-60.3% | -$6.5M-77.8% | -$5.2M-80.0% | -$4.8M-174.2% | -$4.4M-547.3% | -$3.7M-978.8% |
| Retained Earnings | -$39.0M-9.2% | -$38.1M-9.6% | -$37.7M-11.3% | -$37.2M-14.0% | -$35.7M-15.9% | -$34.8M-17.0% | -$33.8M-20.0% | -$32.6M-26.5% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
MDXL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$398K-50.7% | -$294K+6.8% | -$309K+31.1% | -$201K+66.3% | -$264K+70.6% | -$316K+66.3% | -$448K+60.2% | -$598K+39.9% |
| Depreciation & Amortization | $761-41.3% | $903-31.3% | $1K-75.6% | $1K-13.3% | $1K+163.0% | $1K+31.4% | $4K+66.4% | $1K+761.9% |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$1K-264.2% |
| Financing Cash Flow | $397K+55.7% | $273K-17.8% | $352K-21.3% | $203K-61.6% | $255K-68.0% | $332K-67.0% | $447K-61.8% | $527K-25.5% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MDXL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.4%+53.7pp | 72.4%+22.1pp | 57.3%+72.1pp | 48.8%-51.2pp | 3.7%-96.3pp | 50.2%-49.8pp | -14.8%-114.8pp | 100.0% |
| Net Margin | 678.9% | -919.5% | -411.9% | N/A | -1385.6% | -1369.3% | -1568.7% | N/A |
| Return on Assets | 119.9%+319.3pp | -211.9%-12.6pp | -179.1%+18.5pp | N/A | -199.4%-93.2pp | -199.2%-65.4pp | -197.6%-0.9pp | N/A |
| Current Ratio | 0.010.0x | 0.010.0x | 0.010.0x | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.00-0.2x | 0.00-0.3x |
| Asset Turnover | 0.180.0x | 0.23+0.1x | 0.43+0.3x | 0.47+0.4x | 0.14+0.1x | 0.15+0.1x | 0.13+0.1x | 0.020.0x |
Not reported in any period shown, so not listed: Operating Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: Shareholder equity is negative (-$6.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where MEDIXALL GROUP INC Ranks
Frequently Asked Questions
What is MEDIXALL GROUP INC's annual revenue?
MEDIXALL GROUP INC (MDXL) reported $309K in total revenue for fiscal year 2023. This represents a 422.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is MEDIXALL GROUP INC's revenue growing?
MEDIXALL GROUP INC (MDXL) revenue grew by 422.1% year-over-year, from $59K to $309K in fiscal year 2023.
What is MEDIXALL GROUP INC's gross margin?
MEDIXALL GROUP INC (MDXL) had a gross margin of 23.6% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is MEDIXALL GROUP INC's operating cash flow?
MEDIXALL GROUP INC (MDXL) recorded an outflow of $1.2M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are MEDIXALL GROUP INC's total assets?
MEDIXALL GROUP INC (MDXL) had $201K in total assets as of fiscal year 2023, including both current and long-term assets.
What is MEDIXALL GROUP INC's current ratio?
MEDIXALL GROUP INC (MDXL) had a current ratio of 0.00 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
How does MEDIXALL GROUP INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, MEDIXALL GROUP INC (MDXL) held $11K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is MEDIXALL GROUP INC's debt-to-equity ratio negative or not reported?
MEDIXALL GROUP INC (MDXL) has negative shareholder equity of -$6.5M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is MEDIXALL GROUP INC's Piotroski F-Score?
MEDIXALL GROUP INC (MDXL) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.